Virtual high throughput screening (vHTS) - A perspective
Open Access
- 2 September 2008
- journal article
- Published by Biomedical Informatics in Bioinformation
- Vol. 3 (1), 14-17
- https://doi.org/10.6026/97320630003014
Abstract
With the exponential rise in the number of viable novel drug targets, computational methods are being increasingly applied to accelerate the drug discovery process. Virtual High Throughput Screening (vHTS) is one such established methodology to identify drug candidates from large collection of compound libraries. Although it complements the expensive and time consuming High Throughput Screening (HTS) of compound libraries, vHTS possess inherent challenges. The successful vHTS requires the careful implementation of each phase of computational screening experiment right from target preparation to hit identification and lead optimization. This article discusses some of the important considerations that are imperative for designing a successful vHTS experiment.Keywords
This publication has 22 references indexed in Scilit:
- Virtual screening strategies in drug discoveryCurrent Opinion in Chemical Biology, 2007
- Efficient molecular docking of NMR structures: Application to HIV‐1 proteaseProtein Science, 2007
- Molecular docking of balanol to dynamics snapshots of protein kinase AProteins-Structure Function and Bioinformatics, 2005
- Virtual screening of chemical librariesNature, 2004
- Docking and scoring in virtual screening for drug discovery: methods and applicationsNature Reviews Drug Discovery, 2004
- Conformational Flexibility Models for the Receptor in Structure Based Drug DesignCurrent Pharmaceutical Design, 2003
- Implications of protein flexibility for drug discoveryNature Reviews Drug Discovery, 2003
- Virtual screening to enrich hit lists from high‐throughput screening: A case study on small‐molecule inhibitors of angiogeninProteins-Structure Function and Bioinformatics, 2002
- Integration of virtual and high-throughput screeningNature Reviews Drug Discovery, 2002
- Protein flexibility and drug design: how to hit a moving targetCurrent Opinion in Chemical Biology, 2002